IP Library Granted Patent US 9,504,720
Granted Patent B2
US 9,504,720 · App. 13/983,488 · Granted Nov 29, 2016

Substance for preventing and improving arthritis

Inventors: Kikuji Itoh (Tokyo, JP); Shigeru Fujiwara (Kanagawa, JP)
Assignee: Asahi Group Holdings, Ltd.
A61K35/74A23K10/18A23L2/52A23L33/135A61K31/198A61K31/20A61K31/7008A61K31/737A61K35/744A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,504,720
App. No.
13/983,488
Granted
Nov 29, 2016
Kind
B2
Abstract

This application provides a substance containing disrupted cells of an anti-inflammatory lactic acid bacterium and having an effect of preventing or improving arthritis in a subject, a composition containing the substance and the preparation method thereof, and a method for enhancing the effect of preventing and improving arthritis with the use of the substance.

Claims (17)

1. A method for improving one or more symptoms of arthritis in a subject in need thereof comprising:

(a) disrupting cells of a lactic acid bacterium to produce a composition comprising disrupted cells of the lactic acid bacterium;

(b) administering an effective amount of the composition to the subject, wherein the average long diameter and/or surface area of each disrupted cell is 90% or less of that of the lactic acid bacterial cells before disruption.

2. The method of claim 1 , wherein the disrupting step is conducted via physical disruption, chemical treatment, or enzymatic lysis.

3. The method of claim 1 , wherein the lactic acid bacterium is Lactobacillus acidophilus CL-92 strain (FERM BP-4981), Lactobacillus amylovorus CP1563 strain (FERM BP-11255) or Lactobacillus gasseri CP2305 strain (FERM BP-11331), or a mutant strain thereof or derived strain therefrom.

4. The method of claim 1 , wherein the arthritis is rheumatoid arthritis, knee osteoarthritis, tenosynonitis, periomarthritis, tendinitis, or coxitis.

5. The method of claim 1 , wherein the lactic acid bacterium is at least one bacterium belonging to a genus selected from the group consisting of the genera Lactobacillus, Bifidobacterium, Enterococcus, Leuconostoc, Streptococcus, Lactococcus, Pediococcus , and Weissella.

6. The method of claim 5 , wherein the bacterium belonging to the genus Lactobacillus is at least one bacterium selected from the group consisting of Lactobacillus amylovorus, Lactobacillus gasseri, Lactobacillus casei, Lactobacillus paracasei, Lactobacillus zeae, Lactobacillus rhamnosus, Lactobacillus reuteri, Lactobacillus acidophilus, Lactobacillus crispatus, Lactobacillus gallinarum, Lactobacillus brevis, Lactobacillus fermentum, Lactobacillus plantarum, Lactobacillus delbrueckii subsp. bulgaricus, and Lactobacillus johnsonii.

7. The method of claim 1 , further comprising adding at least one known substance having an anti-inflammatory effect to the composition.

8. The method of claim 7 , wherein the known substance having an anti-inflammatory effect is collagen, glucosamine, chondroitin, fatty acid, amino acid, or a salt thereof, or a combination thereof.

9. The method of claim 8 , wherein the combination is with glucosamine or a salt thereof and chondroitin or a salt thereof.

10. A method for decreasing IL-6 expression in a subject in need thereof comprising:

(a) disrupting cells of a lactic acid bacterium to produce a composition comprising disrupted cells of the lactic acid bacterium;

(b) administering an effective amount of the composition to the subject, wherein the average long diameter and/or surface area of each disrupted cell is 90% or less of that of the lactic acid bacterial cells before disruption.

11. The method of claim 10 , wherein the lactic acid bacterium is Lactobacillus acidophilus CL-92 strain (FERM BP-4981), Lactobacillus amylovorus CP1563 strain (FERM BP-11255) or Lactobacillus gasseri CP2305 strain (FERM BP-11331), or a mutant strain thereof or derived strain therefrom.

12. The method of claim 10 , wherein the lactic acid bacterium is at least one bacterium belonging to a genus selected from the group consisting of the genera Lactobacillus, Bifidobacterium, Enterococcus, Leuconostoc, Streptococcus, Lactococcus, Pediococcus , and Weissella.

13. The method of claim 12 , wherein the bacterium belonging to the genus Lactobacillus is at least one bacterium selected from the group consisting of Lactobacillus amylovorus, Lactobacillus gasseri, Lactobacillus casei, Lactobacillus paracasei, Lactobacillus zeae, Lactobacillus rhamnosus, Lactobacillus reuteri, Lactobacillus acidophilus, Lactobacillus crispatus, Lactobacillus gallinarum, Lactobacillus brevis, Lactobacillus fermentum, Lactobacillus plantarum, Lactobacillus delbrueckii subsp. bulgaricus , and Lactobacillus johnsonii.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2016
From: CALPIS CO., LTD.
To: ASAHI GROUP HOLDINGS, LTD.
Reel/Frame 037501/0292 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 2, 2013
From: ITOH, KIKUJI; FUJIWARA, SHIGERU
To: CALPIS CO., LTD.
Reel/Frame 030935/0111 →
Priority Claims (1)
JP 2011-020765 · Feb 2, 2011 · national
Continuity (1)
Related Publication 20130316032A1 · Nov 28, 2013